Invention Grant
US08481583B2 Combination of alpha-2 receptor agonist (clonidin) and anti-muscarinic agent (oxybutynin) for the treatment of sialorrhoea
有权
α-2受体激动剂（可乐定）和抗毒蕈碱剂（奥昔布宁）联合用于治疗唾液
- Patent Title: Combination of alpha-2 receptor agonist (clonidin) and anti-muscarinic agent (oxybutynin) for the treatment of sialorrhoea
- Patent Title (中): α-2受体激动剂（可乐定）和抗毒蕈碱剂（奥昔布宁）联合用于治疗唾液
-
Application No.: US12279217Application Date: 2007-02-12
-
Publication No.: US08481583B2Publication Date: 2013-07-09
- Inventor: Alan Geoffrey Roach , Paul Goldsmith
- Applicant: Alan Geoffrey Roach , Paul Goldsmith
- Applicant Address: WS Apia
- Assignee: Orient Pharma (Samoa) Co., Ltd.
- Current Assignee: Orient Pharma (Samoa) Co., Ltd.
- Current Assignee Address: WS Apia
- Agency: Wilson, Sonsini, Goodrich & Rosati
- Priority: GB0602855.9 20060213; GB0602857.5 20060213
- International Application: PCT/GB2007/050057 WO 20070212
- International Announcement: WO2007/093824 WO 20070823
- Main IPC: A61K31/4168
- IPC: A61K31/4168 ; A61P7/00
Abstract:
An alpha2 adrenoreceptor agonist eg. clonidine, brimonidine, monoxidine, lofexidine is useful for the treatment of sialorrhoea, administered by the paraungual, sublingual or buccal route. The patient to be treated is also given an anti-muscarinic agent eg. oxybutynin, glycopyrrolate, ipratropium.
Public/Granted literature
Information query
IPC分类:
